

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060428 A2

(51) International Patent Classification⁷: A61K 31/135,
A61P 15/00, 25/00

(21) International Application Number: PCT/US02/02039

(22) International Filing Date: 23 January 2002 (23.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/770,665 29 January 2001 (29.01.2001) US

(71) Applicant: SEPRACOR, INC. [US/US]; 111 Locke
Drive, Marlborough, MA 01752 (US).

(72) Inventors: YOUNG, James, W.; 765 Talisman Court,
Palo Alto, CA 94303 (US). JERUSSI, Thomas, P.; 19 Gar-
vey Road, Framingham, MA 01701 (US).

(74) Agent: LAWRENCE, Stanton, T., III; Pennie & Ed-
monds LLP, 1155 Avenue of the Americas, New York, NY
10036 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF USING AND COMPOSITIONS COMPRISING (-)SIBUTRAMINE OPTIONALLY IN COMBINA-
TION WITH OTHER PHARMACOLOGICALLY ACTIVE COMPOUNDS

(57) Abstract: This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; af-
fective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless
leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain,
diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome;
and incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically
pure(-)-sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

WO 02/060428 A2

**METHODS OF USING AND COMPOSITIONS COMPRISING
(-) SIBUTRAMINE OPTIONALLY IN COMBINATION WITH
OTHER PHARMACOLOGICALLY ACTIVE COMPOUNDS**

5 This is a continuation-in-part of U.S. patent application 09/721,669, filed November 27, 2000, which is a continuation of U.S. patent application 08/461,608, both of which are incorporated herein by reference in their entireties.

1. FIELD OF THE INVENTION

10 This invention is directed to methods and compositions for the treatment or prevention of conditions using optically pure (-) sibutramine, optionally in combination with other pharmacologically active compounds.

2. BACKGROUND OF THE INVENTION

15 2.1. SIBUTRAMINE

Sibutramine, chemically named [N-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-N,N-dimethylamine, is a neuronal monoamine reuptake inhibitor which was originally disclosed in U.S. Patent Nos. 4,746,680 and 4,806,570. Sibutramine inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin and dopamine. *See, e.g.,*
20 Buckett *et al.*, *Prog. Neuro-psychopharm. & Biol. Psychiat.*, 12:575-584, 1988; King *et al.*, *J. Clin. Pharm.*, 26:607-611 (1989).

Racemic sibutramine is sold as a hydrochloride monohydrate under the tradename MERIDIA[®], and is indicated for the treatment of obesity. *Physician's Desk Reference*[®] 1494-1498 (53rd ed., 1999).

25 Sibutramine appears to have been extensively studied, and reportedly could be used in the treatment of a variety of disorders. For example, U.S. Patent Nos. 4,552,828, 4,746,680, 4,806,570, and 4,929,629 disclose methods of treating depression using racemic sibutramine, and U.S. Patent Nos. 4,871,774 and 4,939,175 disclose methods of treating Parkinson's disease and senile dementia, respectively, using racemic sibutramine.

30 While racemic sibutramine reportedly can be used in the treatment of a variety of diseases and conditions, it unfortunately has a number of adverse effects. Adverse effects associated with racemic sibutramine include, but are not limited to, significant increases in supine and standing heart rate, including tachycardia, increased blood pressure (hypertension), increased psychomotor activity, dry mouth, dental caries, constipation,

hypohidrosis, blurred or blurry vision, tension, mydriasis, seizures, formation of gallstones, renal/hepatic dysfunction, fevers, arthritis, agitation, leg cramps, hypertonia, abnormal thinking, bronchitis, dyspnea, pruritus, amblyopia, menstrual disorder, ecchymosis/bleeding disorders, interstitial nephritis, and nervousness. These adverse effects may significantly limit the dose level, frequency, and duration of drug therapy.

2.2. AFFECTIVE, CEREBRAL FUNCTION, AND OTHER DISORDERS

This invention concerns, in part, methods of treating and preventing a variety of different diseases and conditions in patients. One is mania, which, like depression, is characterized by changes in mood as the primary symptom. Either of these two extremes of mood may be accompanied by psychosis with disordered thought and delusional perceptions. Psychosis may have, as a secondary symptom, a change in mood, and it is this overlap with depression that causes much confusion in diagnosis. Severe mood changes without psychosis frequently occur in depression and are often accompanied by anxiety.

Other disorders are affective disorders, which are characterized primarily by changes in mood. Major depression is the most common of the significant mental illnesses; it must be distinguished clinically from periods of normal grief, sadness, disappointment, and the related dysphoria or demoralization frequently associated with medical illness. Depression is characterized by feelings of intense sadness, despair, mental slowing, loss of concentration, pessimistic worry, agitation, and self-deprecation. Physical changes can also occur, including insomnia, anorexia, weight loss, decreased energy, loss of libido, and disruption of hormonal circadian rhythms. Often the condition responds to tricyclic or related antidepressant drugs or monoamine oxidase inhibitors.

This invention also concerns the treatment and prevention of dementia, which includes Alzheimer's-type dementia, is produced by a degenerative process involving a loss of cerebral cortical cells; memory loss is a prominent symptom. Dementia is a syndrome of progressive and irreversible dysfunction, presumably caused by cerebral neuropathologic changes and cell loss. The condition is considered to be dominated by cognitive difficulties; depression, paranoia, anxiety, and other psychologic symptoms may also be predominant. In sum, the common clinical profile is one of slow disintegration of both personality and intellect caused by impaired insight and judgment

and by the loss of affect. Dementia is usually insidious, slowly progressive, and usually untreatable. However, in depressed, demented individuals, some antidepressants can significantly improve total function.

Alzheimer's type dementia may also be treated by antidepressant therapy.

- 5 Alzheimer's type dementia (ATD) is a particularly devastating type dementia which affects 30% of humans over 80 years of age (See Evans *et al.*, *J.A.M.A.* 262: 2551-2556, 1989). ATD is a neurodegenerative disease characterized by gradual cognitive impairment. The etiology and pathogenesis of this dementia is associated histopathologically with amyloid plaques, neurofibrillary tangles and loss of neuronal mass primarily in the brain's temporal lobe and neocortex. All of the above mentioned conditions may occur as a result of cerebral function disorders or cerebrovascular disease, and as such, racemic sibutramine may provide treatment and relief from ATD.

- Other disorders of concern are cerebral function disorders, which have a complex etiology. Among their causes are cerebrovascular diseases such as cerebral infarction, cerebral bleeding, cerebral arteriosclerosis, cerebral venous thrombosis, and head injuries and the like. Cerebral function disorders produce a variety of symptoms as secondary diseases, for example, disturbances of consciousness, coma, lowering of attention, amnesic syndrome, senile dementia, speech disorder and the like.

- Another disease of the central nervous system is Parkinson's disease, which is a chronic, progressive central nervous system disorder that usually appears insidiously in the later decades of life. The disease produces a slowly increasing disability in purposeful movement. It is characterized by the major clinical features of tremor, bradykinesia, rigidity, and a disturbance of posture. Patients often have an accompanying dementia. In idiopathic parkinsonism, there is usually a loss of cells in the substantia nigra, locus ceruleus, and other pigmented neurons of the brain, and a decrease of dopamine content in nerve axon terminals of cells projecting from the substantia nigra. The understanding that Parkinson's disease is a syndrome of dopamine deficiency resulted from a series of basic and clinical observations.

This invention is further directed to the treatment and prevention of obesity.

- 30 Obesity is characterized by an accumulation of body fat, to the extent that body weight is 20 percent greater than standard. The importance of the condition is in the number of medical complications to which obese individuals are subject. While the etiology of

obesity is simple and relates to consuming more calories than are expended, many factors contribute to the condition.

The prognosis for obesity is poor; it is a chronic condition that is resistant to treatment and prone to relapse. Caloric reduction through diet, increased physical activity, radical surgical treatment, and medication are considered treatments that may be employed in individual cases. Drug treatment of obesity is often governed by restrictive governmental regulation, and weight gain following this treatment modality is often greater than with other treatments.

10 3. SUMMARY OF THE INVENTION

This invention is directed, in part, to pharmaceutical compositions and dosage forms that comprise racemic sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor. The invention further encompasses pharmaceutical compositions that comprise optically pure (-) sibutramine (*i.e.*, (-) sibutramine substantially free of (+) sibutramine), or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, optionally in combination with a phosphodiesterase inhibitor.

The invention also relates to methods of treating or preventing a variety of diseases and conditions in patients (*e.g.*, mammals such as humans), which comprise the administration of therapeutically or prophylactically effective amounts of racemic sibutramine and a phosphodiesterase inhibitor. Other methods of the invention comprise the administration of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and the optional administration of a therapeutically or prophylactically effective amount of a phosphodiesterase inhibitor. Preferred methods of the invention that comprise the administration of optically pure (-) sibutramine avoid adverse effects associated with racemic sibutramine.

This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic

neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.

3.1. DEFINITIONS

5 As used herein, the term "prodrug" means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (*in vitro* or *in vivo*) to provide the compound. Examples of prodrugs include, but are not limited to, derivatives of (-) sibutramine that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates,
10 biohydrolyzable ureides, and biohydrolyzable phosphates. As used herein, prodrugs of optically pure (-) sibutramine do not include racemic sibutramine.

As used herein, the terms "biohydrolyzable carbamate," "biohydrolyzable carbonate," "biohydrolyzable ureide," "biohydrolyzable phosphate" mean a carbamate, carbonate, ureide, or phosphate, respectively, of a compound that either: 1) does not
15 interfere with the biological activity of the compound but can confer upon that compound advantageous properties *in vivo*, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted *in vivo* to the biologically active compound. Examples of biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, aminoacids, hydroxyalkylamines, heterocyclic
20 and heteroaromatic amines, and polyether amines.

As used herein, the term "biohydrolyzable ester" means an ester of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties *in vivo*, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted *in vivo* to the
25 biologically active compound. Examples of biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters.

As used herein, the term "biohydrolyzable amide" means an amide of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties *in vivo*, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted *in vivo* to the
30 biologically active compound. Examples of biohydrolyzable amides include, but are not

limited to, lower alkyl amides, α -amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.

As used herein, the term "biohydrolyzable ureide" means a ureide of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties *in vivo*, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted *in vivo* to the biologically active compound.

As used herein, the term "biohydrolyzable phosphate" means a phosphate of a compound that either: 1) does not interfere with the biological activity of the compound but can confer upon that compound advantageous properties *in vivo*, such as uptake, duration of action, or onset of action; or 2) is biologically inactive but is converted *in vivo* to the biologically active compound.

As used herein, the term "pharmaceutically acceptable salt" refers to a salt prepared from a pharmaceutically acceptable non-toxic inorganic or organic acid. Inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, and phosphoric. Organic acids include, but are not limited to, aliphatic, aromatic, carboxylic, and sulfonic organic acids including, but not limited to, formic, acetic, propionic, succinic, benzoic camphorsulfonic, citric, fumaric, gluconic, isethionic, lactic, malic, mucic, tartaric, para-toluenesulfonic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic, stearic, sulfanilic, alginic, and galacturonic acid.

As used herein, a composition that is "substantially free" of a compound means that the composition contains less than about 20% by weight, more preferably less than about 10% by weight, even more preferably less than about 5% by weight, and most preferably less than about 3% by weight of the compound.

As used herein, the terms "optically pure," "enantiomerically pure," "pure enantiomer," and "optically pure enantiomer" mean a composition that comprises one enantiomer of a compound and is substantially free of the opposite enantiomer of the compound. A typical optically pure compound comprises greater than about 80% by weight of one enantiomer of the compound and less than about 20% by weight of the opposite enantiomer of the compound, more preferably greater than about 90% by weight

of one enantiomer of the compound and less than about 10% by weight of the opposite enantiomer of the compound, even more preferably greater than about 95% by weight of one enantiomer of the compound and less than about 5% by weight of the opposite enantiomer of the compound, and most preferably greater than about 97% by weight of one enantiomer of the compound and less than about 3% by weight of the opposite enantiomer of the compound. For example, optically pure (-) sibutramine comprises at least about 80% by weight (-) sibutramine and less than about 20% by weight (+) sibutramine.

It should be noted that names used herein to identify compounds of the invention may differ from those that are concordant with International Union of Pure and Applied Chemistry (IUPAC) naming conventions. If there is a discrepancy between a structure depicted herein and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.

4. DETAILED DESCRIPTION OF THE INVENTION

This invention relates, in part, to methods of treating and preventing disorders and conditions in patients that include, but are not limited to: eating disorders such as weight gain and obesity; platelet adhesion; apnea; obsessive-compulsive disorders; affective disorders (*e.g.*, ADHD), depression, or anxiety; male and female sexual function disorders, such as erectile dysfunction; restless leg syndrome; osteoarthritis; irritable bowel syndrome; substance abuse including, nicotine addiction from cigarette smoking or chewing tobacco, and cocaine addiction; migraines; chronic pain; pain, such as neuropathic pain, such as diabetic neuropathy; cerebral function disorders; chronic disorders; and incontinence.

Some methods of the invention comprise administering to a patient in need of treatment or prevention a therapeutically or prophylactically effective amount of racemic sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, in combination with a phosphodiesterase inhibitor.

Other methods of the invention comprise administering to a patient in need of treatment or prevention a therapeutically or prophylactically effective amount of optically

pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, optionally in combination with a phosphodiesterase inhibitor.

Preferred methods of the invention that comprise the administration of a therapeutically or prophylactically effective amount of (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, avoid adverse effects associated with racemic sibutramine.

As used herein, the term "avoid adverse effects" means to incur fewer or none of the adverse effects of the drug referred to, or to incur at least one of those effects to a lesser degree. Thus, a method that avoids adverse effects associated with racemic sibutramine is a method that incurs fewer of the adverse effects of racemic sibutramine, or that incurs at least one of those adverse effects to a lesser degree.

A first embodiment of the invention encompasses a method of treating or preventing a sexual function disorder in a patient in need of such treatment or prevention, which comprises administering to a patient in need of such treatment or prevention therapeutically or prophylactically effective amounts of racemic sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.

Another method of this embodiment is a method of treating or preventing a sexual function disorder in a patient in need of such treatment or prevention, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, optionally in combination with a therapeutically or prophylactically effective amount of a phosphodiesterase inhibitor.

In a preferred method of this embodiment, optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, is administered to a patient orally, transdermally, or mucosally.

In another preferred method of this embodiment, the patient in need of treatment or prevention is elderly or postmenstrual.

As used herein, the terms "sexual dysfunction" and "sexual function disorder" encompass sexual dysfunction in men and women caused by psychological and/or physiological factors. Examples of sexual dysfunction include, but are not limited to,

erectile dysfunction, vaginal dryness, lack of sexual excitement, or inability to obtain orgasm. The term "sexual dysfunction" further encompasses psycho-sexual dysfunction. Examples of psycho-sexual dysfunction include, but are not limited to, inhibited sexual desire, inhibited sexual excitement, inhibited female orgasm, inhibited male orgasm, 5 premature ejaculation, functional dyspareunia, functional vaginismus, and atypical psychosexual dysfunction.

Another embodiment of the invention encompasses a method of treating or preventing an affective disorder in a patient, which comprises administering to a patient in need of such treatment or prevention therapeutically or prophylactically effective 10 amounts of racemic sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.

Another method of this embodiment is a method of treating or preventing an affective disorder in a patient, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically 15 pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, optionally in combination with a therapeutically or prophylactically effective amount of a phosphodiesterase inhibitor.

Affective disorders include, but are not limited to, depression (*e.g.*, melancholia), attention deficit disorder (including attention deficit disorder with hyperactivity and 20 attention deficit/hyperactivity disorder), bipolar and manic conditions, dysthymic disorder, and cyclothymic disorder. As used herein, the terms "attention deficit disorder" (ADD), "attention deficit disorder with hyperactivity" (ADHD), and "attention deficit/hyperactivity disorder" (AD/HD), are used in accordance with their accepted meanings in the art. *See, e.g., Diagnostic and Statistical Manual of Mental Disorders*, 25 *Fourth Ed., American Psychiatric Association, 1997 (DSM-IV™)* and *Diagnostic and Statistical Manual of Mental Disorders, 3rd Ed., American Psychiatric Association (1981) (DSM-III™)*.

A preferred method of this embodiment is a method of treating or preventing attention deficit disorder in children (*e.g.*, ages 3-18). Another preferred method of this 30 embodiment is a method of treating or preventing depression.

As used herein, the term "treating or preventing depression" means relief from or prevention of the symptoms of depression which include, but are not limited to, changes

in mood, feelings of intense sadness, despair, mental slowing, loss of concentration, pessimistic worry, agitation, and self-deprecation. Physical changes can also be relieved or prevented by this method, and include, but are not limited to, insomnia, anorexia, decreased energy and libido, and abnormal hormonal circadian rhythms.

5 Another embodiment of the invention encompasses a method of treating or preventing weight gain or obesity in a patient, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, optionally in combination with a lipase inhibitor.

10 As used herein, the term "treating or preventing weight gain or obesity" means reduction of weight, relief from being overweight, treating weight gain caused by the administration of other drugs, relief from gaining weight, or relief from obesity, and prevention from gaining weight, all of which are usually due to unnecessary consumption of food. The invention also encompasses methods of treating or preventing conditions
15 incidental to obesity including, but not limited to, hypertension, such as pulmonary hypertension; cancers, such as breast, colon, gall bladder, and endometrial; gall stones; cardiovascular disease, such as dyslipidemia and carotid intimal medial thickening; hiatal hernia; osteoarthritis; gout; thyroid disease, such as diabetes; gastro-esophageal reflux disease; menstrual dysfunction; and infertility.

20 Another embodiment encompasses a method of treating or preventing a disorder associated with the administration of a lipase inhibitor for obesity or weight management, such as, for example, orlistat (XENICAL®), which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of racemic sibutramine or optically pure (-) sibutramine, or a pharmaceutically
25 acceptable salt, solvate, hydrate, clathrate, or prodrug thereof. As used herein, the term "treating or preventing a disorder associated with the administration of a lipase inhibitor" means alleviating or reducing adverse effects associated with administration of a lipase inhibitor, which include, but are not limited to, infectious diarrhea, oily fecal spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased
30 defecation, anal leakage, and fecal incontinence.

 Another embodiment of the invention encompasses a method of treating or preventing cerebral function disorder, which comprises administering to a patient in need

of such treatment or prevention therapeutically or prophylactically effective amounts of racemic sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.

Another method of this embodiment is a method of treating or preventing a cerebral function disorder in a patient, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, optionally in combination with a therapeutically or prophylactically effective amount of a phosphodiesterase inhibitor.

Cerebral function disorders include, but are not limited to, senile dementia, Alzheimer's type dementia, memory loss, amnesia/amnestic syndrome, disturbance of consciousness, coma, lowering of attention, speech disorders, Parkinson's disease, Lennox syndrome, autism, epilepsy, hyperkinetic syndrome, and schizophrenia. Cerebral function disorders can be induced by factors including, but not limited to, cerebrovascular diseases, such as cerebral infarction, cerebral bleeding, cerebral arteriosclerosis, cerebral venous thrombosis, and head injuries, and conditions having symptoms selected from the group consisting of disturbances of consciousness, senile dementia, coma, lowering of attention, and speech disorders. As used herein, the term "treating or preventing a cerebral function disorder" means relief from or prevention of one or more symptoms associated with cerebral function disorders.

Another embodiment encompasses a method of treating or preventing restless leg syndrome, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of racemic sibutramine or optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof. In a particular method of this embodiment, the racemic or optically pure sibutramine is administered in combination with a phosphodiesterase inhibitor.

In a preferred embodiment, the patient is at least about 50, 60, or 70 years of age. In another preferred method of this embodiment, the racemic or optically pure sibutramine is administered in combination with at least one of pergolide, carbidopa, levodopa, oxycodone, carbamazepine, gabapentin, or pharmaceutically acceptable salts,

solvates, hydrates, clathrates, prodrugs, optically and pharmacologically active stereoisomers, or pharmacologically active metabolites thereof.

As used herein, the term "restless leg syndrome" encompasses a disorder that typically occurs during sleep or rest, or just before sleep or rest, and which is characterized by uncomfortable sensations in the legs. The disorder often occurs in patients older than about 50 years of age. Examples of uncomfortable sensations in the legs include, but are not limited to, pulling, drawing, crawling, wormy, boring, tingling, pins and needles, prickly and sometimes painful sensations that are usually accompanied by an overwhelming urge to move the legs. As used herein, the term "restless leg syndrome" also encompasses Ekbom Syndrome, Wittmaack-Ecbom Syndrome, Hereditary Acromelalgia, and Anxieties Tibialis.

Another embodiment of the invention encompasses a method of treating or preventing pain in a patient, which comprises administering to a patient in need of such treatment or prevention therapeutically or prophylactically effective amounts of racemic sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.

Another method of this embodiment is a method of treating or preventing pain in a patient, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, optionally in combination with a therapeutically or prophylactically effective amount of a phosphodiesterase inhibitor.

Another method of this embodiment is a method of treating or preventing an obsessive-compulsive disorder in a patient in need of such treatment or prevention, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.

As used herein, the terms "obsessive-compulsive disorder," "pre-menstrual syndrome," "anxiety," and "eating disorder" are used consistently with their accepted meanings in the art. *See, e.g.*, DSM-IV™ and DSM-III™. The term "methods of treating or preventing" when used in connection with these disorders means the amelioration, prevention, or relief from symptoms and/or effects associated with these disorders.

Another embodiment encompasses a method of treating or preventing substance abuse which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof. In a particular embodiment, the substance abuse is cocaine addiction or alcohol addiction.

As used herein, the term "substance abuse" encompasses the abuse of, and physical and/or psychological addiction to, drugs or alcohol. The term "substance abuse" further encompasses its accepted meaning in the art. *See, e.g.*, DSM-IV™ and DSM-III™. A preferred method encompassed by this embodiment is a method of treating or preventing cocaine and/or heroin abuse.

Another embodiment encompasses a method of treating or preventing nicotine addiction which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof. Nicotine addiction includes nicotine addiction of all known forms, such as addiction to cigarettes, cigars and/or pipes, and chewing tobacco.

Another embodiment encompasses a method of eliciting smoking cessation which comprises administering to a patient who smokes tobacco a therapeutically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof. In a preferred method encompassed by this embodiment, optically pure (-) sibutramine, or pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, is administered orally, mucosally, or transdermally. In a more preferred method, optically pure (-) sibutramine or pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof is administered transdermally.

In another preferred method of this embodiment, optically pure (-) sibutramine, or pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, is administered in combination with a therapeutically or prophylactically effective amount of nicotine. Preferably, the nicotine and/or optically pure (-) sibutramine or pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof is administered orally, mucosally, or transdermally. More preferably, the nicotine and/or optically pure (-) sibutramine or pharmaceutically acceptable salt, solvate, ester, clathrate, or prodrug thereof is administered transdermally.

Another method encompassed by this embodiment is a method of treating or preventing weight gain associated with smoking cessation which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.

Another embodiment encompasses a method of treating or preventing weight gain associated with the administration of other drugs that may induce weight gain, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, ester, clathrate, or prodrug thereof.

Another embodiment encompasses a method of treating or preventing a chronic disorder including, but not limited to, narcolepsy, chronic fatigue syndrome, seasonal affective disorder, fibromyalgia, and premenstrual syndrome (or premenstrual dysphoric disorder), which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof. Preferred methods are methods of treating or preventing narcolepsy, premenstrual syndrome, or chronic fatigue syndrome.

Another embodiment encompasses a method of treating or preventing anxiety which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.

Another embodiment encompasses a method of treating or preventing an eating disorder including, but not limited to, anorexia, bulimia, bingeing, and snacking, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.

Another embodiment of the invention encompasses a method of treating or preventing migraines in a patient in need of such treatment or prevention, which comprises administering to a patient in need of such treatment or prevention therapeutically or prophylactically effective amounts of racemic sibutramine, or a pharmaceutically

acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.

Another method of this embodiment is a method of treating or preventing migranes in a patient in need of such treatment or prevention, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, optionally in combination with a therapeutically or prophylactically effective amount of a phosphodiesterase inhibitor.

Another embodiment encompasses a method of treating or preventing incontinence which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, ester, clathrate, or prodrug thereof. In particular, optically pure (-) sibutramine can be used to treat fecal incontinence, stress urinary incontinence ("SUI"), urinary exertional incontinence, urge incontinence, reflex incontinence, passive incontinence, anal leakage, and overflow incontinence.

As used herein, the term "treating or preventing incontinence" means treatment, prevention of, or relief from the symptoms of incontinence including involuntary voiding of feces or urine, and dribbling or leakage of feces or urine, which may be due to one or more causes including, but not limited to, pathology altering sphincter control, loss of cognitive function, overdistention of the bladder, hyper-reflexia and/or involuntary urethral relaxation, weakness of the muscles associated with the bladder or neurologic abnormalities.

A preferred method encompassed by this embodiment is a method of treating or preventing stress urinary incontinence. In a further preferred method encompassed by this embodiment, the patient is an elder human of an age greater than about 50 or a child of an age less than about 13.

In a specific embodiment of each of the methods of the invention, a therapeutically or prophylactically effective amount of optically pure (-) sibutramine is administered to a patient in combination with an additional pharmacologically active compound. Examples of additional pharmacologically active compounds include, but are

not limited to, phosphodiesterase inhibitors and lipase inhibitors. As discussed in more detail herein, the particular additional pharmacologically active compound used in a method will depend upon the disease or condition being treated or prevented, as well as the particular patient being treated.

5 The invention also encompasses pharmaceutical compositions and single unit dosage forms that can be used, for example, in the methods described herein. One embodiment of the invention encompasses a pharmaceutical composition or dosage form that comprises optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof. Other pharmaceutical compositions and
10 single unit dosage forms of the invention comprise racemic sibutramine or optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and an additional pharmacologically active compound.

4.1. PREPARATION OF (-) SIBUTRAMINE

15 The optically purified stereoisomers of sibutramine are most readily obtained by resolving the racemic mixture of sibutramine prepared by following the synthetic procedures disclosed herein or those described in U.S. Patent Nos. 4,522,828 and 4,476,680, the disclosures of which are hereby incorporated by reference. A preferred technique is resolution by fractional crystallization of diastereomeric salts formed with
20 optically active resolving agents. *See, e.g., "Enantiomers, Racemates and Resolutions,"* by J. Jacques, A. Collet, and S.H. Wilen, (Wiley-Interscience, New York, 1981); S.H. Wilen, A. Collet, and J. Jacques, *Tetrahedron*, 2725 (1977); E.L. Eliel *Stereochemistry of Carbon Compounds* (McGraw-Hill, NY, 1962); and S.H. Wilen *Tables of Resolving Agents and Optical Resolutions* 268 (E.L. Eliel ed., Univ. of Notre Dame Press, Notre
25 Dame, IN, 1972).

 Since sibutramine is a basic amine, diastereomeric salts suitable for separation by fractional crystallization are readily formed by addition of chiral acid resolving agents in optically pure form. Suitable resolving agents for use herein include optically pure tartaric acid and its derivatives, camphorsulfonic acid, mandelic acid and derivatives
30 thereof, and other optically active acids. The desired (-) sibutramine isomer may be recovered either from the crystallized diastereomer or from the mother liquor, depending on the solubility properties of the particular acid resolving agent employed and depending

on the particular acid enantiomer used. The identity and optical purity of the particular sibutramine isomer so recovered may be determined by polarimetry or other analytical methods.

5

4.2. METHODS OF TREATMENT AND PREVENTION

In each of the methods of the invention, a therapeutically or prophylactically effective amount of racemic sibutramine or optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, is administered to a patient.

10

The magnitude of a prophylactic or therapeutic dose of racemic sibutramine or optically pure (-) sibutramine in the acute or chronic management of disease will vary with the severity of the condition to be treated and the route of administration. The dose and perhaps the dose frequency will also vary according to age, body weight, response, and the past medical history of the individual patient. In general, the recommended daily dose range for the conditions described herein lie within the range of from about 1 mg to about 60 mg per day, given as a single once-a-day dose in the morning or as divided doses throughout the day. Preferably, a daily dose range should be from about 2 mg to about 50 mg per day; and most preferably, a daily dose range should be between about 5 mg and about 30 mg per day. In managing the patient, the therapy should be initiated at a lower dose, perhaps about 5 to about 15 mg, and increased if necessary up to about 5 mg per day as either a single dose or divided doses, depending on the patient's global response. It is further recommended that patients aged over 65 years should receive doses in the range of about 5 to about 30 mg per day depending on global response. It may be necessary to use dosages outside these ranges.

25

Optionally, racemic sibutramine or optically pure (-) sibutramine is adjunctively administered (*i.e.*, administered in combination) with one or more additional pharmacologically active compounds. For example, optically pure (-) sibutramine and an additional pharmacologically active compound can be administered to a patient as a combination, concurrently but separately, or sequentially by any suitable route. Suitable routes of administration include oral, mucosal (*e.g.*, nasal, sublingual, buccal, rectal, and vaginal), parenteral (*e.g.*, intravenous, intramuscular or subcutaneous), and transdermal routes.

30

As physicians and those skilled in the art of pharmacology will readily appreciate, the particular additional pharmacologically active compounds that can be administered in combination with a optically pure (-) sibutramine will depend on the particular disease or condition being treated or prevented, and may also depend on the age and health of the patient to which the compounds are to be administered.

Additional pharmacologically active compounds that can be used in the methods and compositions of the invention include, but are not limited to, phosphodiesterase and lipase inhibitors. Examples of phosphodiesterase inhibitors that can be used in compositions and methods of the invention include, but are not limited to, those disclosed in U.S. Patent No. 5,250,534; U.S. Patent No. 5,719,283; U.S. Patent No. 6,127,363; WO 94/28902; WO 97/03675; WO 98/06722, all of which are expressly incorporated herein by reference in their entirety. Preferred phosphodiesterase inhibitors are PDE5 and PDE6 inhibitors. Particular phosphodiesterase inhibitors include, but are not limited to, sildenafil (Viagra[®]), desmethylsildenafil, vinopocetine, milrinone, amrinone, pimobendan, cilostamide, enoximone, peroximone, vesnarinone, rolipran, R020-1724, zaprinast, dipyridamole, and pharmaceutically acceptable salts, solvates, hydrates, clathrates, prodrugs, optically and pharmacologically active stereoisomers, and pharmacologically active metabolites thereof.

Suitable daily dosage ranges of additional pharmacologically active compounds that can be adjunctively administered with racemic sibutramine or optically pure (-) sibutramine can be readily determined by those skilled in the art following dosages reported in the literature and recommended in the *Physician's Desk Reference*[®].

For example, suitable daily dosage ranges of phosphodiesterase inhibitors can be readily determined by those skilled in the art. In general, the total daily dose of a phosphodiesterase inhibitor will be from about 0.5 mg to about 500 mg, from about 1 mg to about 350 mg, or from about 2 mg to about 250 mg.

The dosage amounts and frequencies provided herein are encompassed by the terms "therapeutically effective," "prophylactically effective," and "therapeutically or prophylactically effective" as used herein. When used in connection with an amount of optically pure (-) sibutramine, these terms further encompass an amount of optically pure (-) sibutramine that induces fewer or less severe adverse effects than are associated with the administration of racemic sibutramine. Adverse effects associated with racemic

sibutramine include, but are not limited to, significant increases in supine and standing heart rate, including tachycardia, increased blood pressure (hypertension), increased psychomotor activity, dry mouth, dental caries, constipation, hypohidrosis, blurred or blurry vision, tension, mydriasis, seizures, formation of gallstones, renal/hepatic dysfunction, fevers, arthritis, agitation, leg cramps, hypertonia, abnormal thinking, bronchitis, dyspnea, pruritus, amblyopia, menstrual disorder, ecchymosis/bleeding disorders, interstitial nephritis, and nervousness. However, the induction of fewer or less severe adverse-effects is attributable to the administration of a sibutramine metabolite and the efficacy of which may be less apparent or absent with the administration of a combination therapy.

4.3. PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS

Pharmaceutical compositions and dosage forms of the invention comprise one or more of the active ingredients disclosed herein (*e.g.*, (-) sibutramine, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof). Pharmaceutical compositions and dosage forms of the invention typically also comprise one or more pharmaceutically acceptable excipients or diluents.

Single unit dosage forms of the invention are suitable for oral, mucosal (*e.g.*, nasal, sublingual, vaginal, buccal, or rectal), parenteral (*e.g.*, subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), or transdermal administration to a patient. Examples of dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (*e.g.*, nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (*e.g.*, aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (*e.g.*, crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.

The composition, shape, and type of dosage forms of the invention will typically vary depending on their use. For example, a dosage form used in the acute treatment of sexual dysfunction or a related disorder may contain larger amounts of one or more of the

active ingredients it comprises than a dosage form used in the chronic treatment of sexual dysfunction. Similarly, a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease or disorder. These and other ways in which specific dosage forms encompassed by this invention will vary from one another will be readily apparent to those skilled in the art. *See, e.g., Remington's Pharmaceutical Sciences*, 18th ed., Mack Publishing, Easton PA (1990).

Typical pharmaceutical compositions and dosage forms comprise one or more excipients. Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient. For example, oral dosage forms such as tablets may contain excipients not suited for use in parenteral dosage forms. The suitability of a particular excipient may also depend on the specific active ingredients in the dosage form. For example, the decomposition of some active ingredients can be accelerated by some excipients such as lactose, or when exposed to water. Active ingredients that comprise primary or secondary amines are particularly susceptible to such accelerated decomposition. Consequently, this invention encompasses pharmaceutical compositions and dosage forms that contain little, if any, lactose or other mono- or di-saccharides. As used herein, the term "lactose-free" means that the amount of lactose present, if any, is insufficient to substantially increase the degradation rate of an active ingredient.

Lactose-free compositions of the invention can comprise excipients that are well known in the art and are listed, for example, in the U.S. Pharmacopia (USP) SP (XXI)/NF (XVI). In general, lactose-free compositions comprise active ingredients, a binder/filler, and a lubricant in pharmaceutically compatible and pharmaceutically acceptable amounts. Preferred lactose-free dosage forms comprise active ingredients, microcrystalline cellulose, pre-gelatinized starch, and magnesium stearate.

This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising active ingredients, since water can facilitate the degradation of some compounds. For example, the addition of water (*e.g.*, 5%) is widely accepted in the

pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. *See, e.g.,* Jens T. Carstensen, *Drug Stability: Principles & Practice*, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-80. In effect, water and heat accelerate the decomposition of some
5 compounds. Thus, the effect of water on a formulation can be of great significance since moisture and/or humidity are commonly encountered during manufacture, handling, packaging, storage, shipment, and use of formulations.

Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low
10 humidity conditions. Pharmaceutical compositions and dosage forms that comprise lactose and at least one active ingredient that comprises a primary or secondary amine are preferably anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.

An anhydrous pharmaceutical composition should be prepared and stored such
15 that its anhydrous nature is maintained. Accordingly, anhydrous compositions are preferably packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (*e.g.,* vials), blister packs, and strip packs.

20 The invention further encompasses pharmaceutical compositions and dosage forms that comprise one or more compounds that reduce the rate by which an active ingredient will decompose. Such compounds, which are referred to herein as "stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers.

25 Like the amounts and types of excipients, the amounts and specific types of active ingredients in a dosage form may differ depending on factors such as, but not limited to, the route by which it is to be administered to patients. However, typical dosage forms of the invention comprise optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, or prodrug thereof in an amount of from about 1 mg to
30 about 60 mg, preferably in an amount of from about 3 mg to about 50 mg, more preferably in an amount of from about 5 mg to about 30 mg, and most preferably in an amount of from about 10 mg to about 25 mg.

4.3.1. ORAL DOSAGE FORMS

Pharmaceutical compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups). Such dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. *See generally, Remington's Pharmaceutical Sciences*, 18th ed., Mack Publishing, Easton PA (1990).

Typical oral dosage forms of the invention are prepared by combining the active ingredient(s) in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques. Excipients can take a wide variety of forms depending on the form of preparation desired for administration. For example, excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents. Examples of excipients suitable for use in solid oral dosage forms (e.g., powders, tablets, capsules, and caplets) include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.

Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by any of the methods of pharmacy. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.

For example, a tablet can be prepared by compression or molding. Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with an excipient. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

Examples of excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants. Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not

limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (*e.g.*, ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl
5 cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (*e.g.*, Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.

Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH-101, AVICEL-PH-103 AVICEL RC-581, AVICEL-PH-105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus
10 Hook, PA), and mixtures thereof. An specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL RC-581. Suitable anhydrous or low moisture excipients or additives include AVICEL-PH-103™ and Starch 1500 LM.

Examples of fillers suitable for use in the pharmaceutical compositions and
15 dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (*e.g.*, granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage
20 form.

Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions. Thus, a sufficient amount of
25 disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention. The amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art. Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, preferably from about
30 1 to about 5 weight percent of disintegrant.

Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate,

microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrillin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other alginates, other celluloses, gums, and mixtures thereof.

Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof. Additional lubricants include, for example, a syloid silica gel (AEROSIL 200, manufactured by W.R. Grace Co. of Baltimore, MD), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Plano, TX), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA), and mixtures thereof. If used at all, lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.

4.3.2. DELAYED RELEASE DOSAGE FORMS

Active ingredients of the invention can be administered by controlled release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of which is incorporated herein by reference. Such dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention. The invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled-release.

All controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance. In addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood levels of the drug, and can thus affect the occurrence of side (*e.g.*, adverse) effects.

Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, temperature, enzymes, water, or other physiological conditions or compounds.

4.3.3. PARENTERAL DOSAGE FORMS

Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.

Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride

Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

- 5 Compounds that increase the solubility of one or more of the active ingredients disclosed herein can also be incorporated into the parenteral dosage forms of the invention.

10 **4.3.4. TRANSDERMAL, TOPICAL,
 AND MUCOSAL DOSAGE FORMS**

- Transdermal, topical, and mucosal dosage forms of the invention include, but are not limited to, ophthalmic solutions, sprays, aerosols, creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. *See, e.g., Remington's Pharmaceutical Sciences*, 16th and 18th eds., Mack Publishing, Easton PA (1980 & 1990); and *Introduction to Pharmaceutical Dosage Forms*, 4th ed., Lea & Febiger, Philadelphia (1985). Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels. Further, transdermal dosage forms include "reservoir type" or "matrix type" patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredients.

- Suitable excipients (*e.g.*, carriers and diluents) and other materials that can be used to provide transdermal, topical, and mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied. With that fact in mind, typical excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form lotions, tinctures, creams, emulsions, gels or ointments, which are non-toxic and pharmaceutically acceptable. Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. *See, e.g., Remington's Pharmaceutical Sciences*, 16th and 18th eds., Mack Publishing, Easton PA (1980 & 1990).

Depending on the specific tissue to be treated, additional components may be used prior to, in conjunction with, or subsequent to treatment with active ingredients of the invention. For example, penetration enhancers can be used to assist in delivering the active ingredients to the tissue. Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).

The pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied, may also be adjusted to improve delivery of one or more active ingredients. Similarly, the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery. Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery. In this regard, stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent. Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.

4.3.5. KITS

Typically, active ingredients of the invention are preferably not administered to a patient at the same time or by the same route of administration. This invention therefore encompasses kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.

A typical kit of the invention comprises a unit dosage form of racemic sibutramine or optically pure (-) sibutramine, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, and a unit dosage form of a second active ingredient. Examples of second active ingredients include, but are not limited to, phosphodiesterase inhibitors and lipase inhibitors.

Kits of the invention can further comprise devices that are used to administer the active ingredients. Examples of such devices include, but are not limited to, syringes, drip bags, patches, and inhalers.

Kits of the invention can further comprise pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients. For example, if an active ingredient is provided in a solid form that must be reconstituted for parenteral administration, the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration. Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

5. EXAMPLES

5.1. EXAMPLE 1: SYNTHESIS AND OPTICAL RESOLUTION OF SIBUTRAMINE

20 Synthesis of 1-(4-Chlorophenyl)cyclobutanecarbonitrile

To a suspension of NaH (17.6 g 60%, washed with hexane) in dimethylsulfoxide (150 mL) at room temperature with mechanical stirring was added over a one hour period a mixture of chlorbenzyl nitrile (30.3 g) and 1,3-dibromopropane (22.3 mL, 44.5 g). The reaction mixture was stirred for an additional 1 hour, and isopropyl alcohol (10 mL) was added slowly to quench excess NaH. Water (150 mL) was added. The reaction mixture was extracted with *t*-butyl methyl ether (MTBE) (2 x 200 mL), and the combined extracts were washed with water (3 x 200 mL), brine, and dried over MgSO₄. The solvent was removed in a rotoevaporator, and the final product was purified by distillation to give the title compound (22 g, 56%) as pale yellow oil, bp 110-120°C/1.0 mm Hg. The product was characterized by ¹H NMR.

Synthesis of 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine

A solution of isobutylmagnesium bromide (2M, 108 mL) in diethyl ether (Aldrich) was concentrated to remove most of the ether. The residue was dissolved in toluene (150 mL), followed by addition of the nitrile made above (22 g). The reaction mixture was heated to 105°C for 17 hours. The reaction mixture was cooled to room temperature, and added to a slurry of NaBH₄ in isopropyl alcohol (450 mL). The reaction mixture was heated under reflux for 6 hours, cooled to room temperature and concentrated. The residue was diluted with water (350 mL), and extracted with ethyl acetate (3 x 200 mL). The combined extracts were washed with water (100 mL), and dried (MgSO₄), and concentrated to give 24.2 g crude product (83%).

Synthesis of Sibutramine Free Base

1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine (21.6 g) was added to formic acid (27 mL) and aqueous formaldehyde (46 mL). The reaction mixture was heated to 85-95°C for 18 hours and was cooled to room temperature. 30% NaOH was added until the mixture was basic (pH > 11). The solution was extracted with chloroform (3 x 200 mL) and the extracts were combined and washed with water and brine and concentrated to give 15 g product.

Sibutramine HCl

Sibutramine free base (2.25 g) was dissolved in MTBE (20 mL) and that solution was added to 20 mL 1M HCl in diethyl ether. The reaction mixture was stirred for 30 minutes, and the solid was collected by filtration to give 1.73 g after drying. The product was characterized by ¹H NMR.

Resolution of Sibutramine

12.3 g racemic sibutramine was dissolved in ethyl acetate (85 mL), and a solution of 21.7 g L-dibenzyltartaric acid ("L-DBTA") in ethyl acetate (85 mL) was added thereto. The reaction mixture was heated to reflux and cooled to room temperature. The white precipitate was collected (ee of salt is ca 85%). The solid was then suspended in 220 mL ethyl acetate and heated at reflux for 30 minutes. The solid was collected to give >95% ee. The salt was further crystallized in isopropyl alcohol (450 mL) to give 11.3 g of salt

with >99.3% ee. (-)-Sibutramine L-DBTA (yield 76%). Free base was obtained by treatment of the salt with saturated aqueous NaHCO_3 and extracted with chloroform. The (-)-sibutramine HCl salt was obtained with treatment of the free base with $\text{HCl}/\text{Et}_2\text{O}$ as described above. Optical rotation of the HCl salt was $[\alpha] = 3.15$ ($c = 0.9$, H_2O), ^1H NMR ^{13}C (CD_3OD), and $M^+ = 279$. The resolution mother liquor was treated with NaOH to give the partially enriched (+)-sibutramine and was then treated with D-DBTA as described above to give (+)-sibutramine-D-DBTA salt with > 99.3% ee. The sibutramine enantiomers were characterized by ^1H and ^{13}C NMR: $M^+ = 279$. The material was also characterized by HPLC and Chiral HPLC.

10

5.2. EXAMPLE 2: PHARMACOLOGICAL STUDY OF RACEMIC AND OPTICALLY PURE SIBUTRAMINE

A pharmacologic study is conducted to determine the relative potency, comparative efficacy, binding affinity, and toxicity of the enantiomers and racemic mixture of sibutramine. The profile of relative specificity of monoamine reuptake inhibition is determined from the compound's inhibition of norepinephrine (NE) (variously known as noradrenaline) reuptake in brain tissue with that of the inhibition of dopamine (DA) and serotonin (5HT) reuptake.

High-affinity uptake of the ^3H -radiomonoamines is studied in synaptosomal preparations prepared from rat corpus striatum (for inhibition of DA reuptake) and cerebral cortex (for 5HT and NE) using methods published by Kula et al., *Life Sciences* 34(26): 2567-2575, 1984, and Baldessarini et al., *Life Sciences* 39: 1765-1777, 1986. Tissues are freshly dissected on ice and weighed. Following homogenization by hand (14 strokes in 10-35 vols of ice-cold isotonic 0.32M sucrose, containing nilamide, 34 μM) in a Teflon-on-glass homogenizer, the tissue is centrifuged for ten (10) minutes at 900 x g; the supernatant 'solution' that results contains synaptosomes that are used without further treatment. Each assay tube contains 50 μL of the cerebral homogenate, radiolabelled- ^3H -monoamine, and the test compound (e.g., the pure sibutramine enantiomers, the racemate, and appropriate standards) in a freshly prepared physiologic buffer solution with a final volume of 0.5 mL. Tissues are preincubated for 15 minutes at 37°C before the assay. Tubes are held on ice until the start of incubation which is initiated by adding ^3H -amine to provide a final concentration of 0.1 MM. Tubes are incubated at 37°C for 10 minutes with ^3H -DA (26 Ci/mmol) and for 20 minutes with ^3H -5HT (about 20 Ci/mmol) and ^3H -

NE (about 20 Ci/mmol). The specific activity of the radiomonoamine will vary with available material and is not critical. The reaction is terminated by immersion in ice and dilution with 3 ml of ice cold isotonic saline solution containing 20 mM TRIS buffer (pH 7.0). These solutions are filtered through cellulose ester microfilters, followed by

5 washing with two 3 mL volumes of the same buffer. The filter is then counted for ^3H -radioactivity in 3.5 mL of Polyfluor at ~ 50% efficiency for tritium. Blanks (either incubated at 0°C or incubated with specific, known uptake inhibitors of DA [GRB-12909, 10 MM], 5HT- zimelidine 10 μM], or of NE [desipramine 10 μM]) are usually indistinguishable from assays performed without tissue and average 2-3% of total CPM.

10 Comparison of the amounts of ^3H -radioactivity retained on the filters provides an indication of the relative abilities of the pure enantiomers and racemic mixture of sibutramine (and of known DA-, 5HT-, or NE-reuptake inhibitors) to block the reuptake of these monoamines in those tissues. This information is useful in gauging the relative potency and efficacy of racemic sibutramine and its enantiomers.

15 The acute toxicities of the enantiomers of sibutramine and of the racemic mixture thereof are determined in studies in which rats are administered progressively higher doses (mg/kg) of the pure isomers or racemate. That lethal dose which, when administered orally, causes death of 50% of the test animals, is reported as the LD_{50} . Comparison of LD_{50} values for the enantiomers and racemate provides a measure of the
20 relative toxicity of the compositions.

5.3. EXAMPLE 2: ORAL FORMULATIONS

CAPSULES

25	<u>Formula</u>	<u>Quantity per Capsule in mg</u>		
		<u>A</u>	<u>B</u>	<u>C</u>
	Active ingredient (-) sibutramine	10.0	20.0	30.0
	Lactose	70.0	60.0	95.0
	Corn Starch	19.5	19.5	24.5
30	Magnesium Stearate	<u>0.05</u>	<u>0.05</u>	<u>0.05</u>
	Compression Weight	100.0	100.0	150.0

The active ingredient, (-) sibutramine, the lactose and corn starch are blended until uniform; then the magnesium stearate is blended into the resulting powder. The resulting mixture is encapsulated into suitably sized two-piece hard gelatin capsules.

5

TABLETS

<u>Formula</u>	<u>Quantity per Tablet in mg</u>		
Active ingredient	<u>A</u>	<u>B</u>	<u>C</u>
(-) sibutramine	10	20	30
Lactose	94	84	74
10 Starch BP	30	30	30
Pregelatinized Maize Starch	15	15	15
Magnesium Stearate	1	1	1
Compression Weight	150	150	150

15

The active ingredients sieved through a suitable sieve and blended with lactose, starch, and pregelatinized maize starch. Suitable volumes of purified water are added, and the powders are granulated. After drying, the granules are screened and blended with the magnesium stearate. The granules are then compressed into tablets using punches.

Tables of other strengths may be prepared by altering the ratio of active ingredient to lactose or to the compression weight and using punches to suit.

20

CLAIMS

What is claimed is:

1. A method of treating or preventing a sexual function disorder in a patient,
5 which comprises administering to a patient in need of such treatment or prevention therapeutically or prophylactically effective amounts of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.
- 10 2. A method of treating or preventing an affective disorder in a patient in need of such treatment or prevention, which comprises administering to a patient in need of such treatment or prevention therapeutically or prophylactically effective amounts of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.
- 15 3. The method of claim 2 wherein the affective disorder is attention deficit disorder, depression, or anxiety.
- 20 4. A method of treating or preventing weight gain or obesity in a patient, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, optionally in combination with a lipase inhibitor.
- 25 5. A method of treating or preventing a disorder associated with the administration of a lipase inhibitor for obesity or weight management, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.
- 30 6. A method of treating or preventing cerebral function disorder in a patient, which comprises administering to a patient in need of such treatment or prevention

therapeutically or prophylactically effective amounts of racemic sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.

5 7. The method of claim 6 wherein the cerebral function disorder is senile dementia, Alzheimer's type dementia, memory loss, amnesia/amnestic syndrome, disturbance of consciousness, coma, lowering of attention, speech disorders, Parkinson's disease, Lennox syndrome, autism, epilepsy, hyperkinetic syndrome, or schizophrenia.

10 8. A method of treating or preventing restless leg syndrome, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof.

15 9. The method of claim 8 which further comprises the administration of pergolide, carbidopa, levodopa, oxycodone, carbamazepine, or gabapentin, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, prodrug, optically and pharmacologically active stereoisomer, or pharmacologically active metabolite thereof.

20 10. A method of treating or preventing pain in a patient, which comprises administering to a patient in need of such treatment or prevention therapeutically or prophylactically effective amounts of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.

25 11. A method of treating or preventing a migraine in a patient, which comprises administering to a patient in need of such treatment or prevention therapeutically or prophylactically effective amounts of optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a
30 phosphodiesterase inhibitor.

12. The method of claim 1, 2, 4, 6, 8, 10, or 11 wherein the therapeutically or prophylactically effective amount of optically pure (-) sibutramine is from about 1 mg to about 60 mg per day.

5 13. The method of claim 12 wherein the therapeutically or prophylactically effective amount of optically pure (-) sibutramine is from about 2 mg to about 50 mg per day.

10 14. The method of claim 13 wherein the therapeutically or prophylactically effective amount of optically pure (-) sibutramine is from about 5 mg to about 30 mg per day.

15 15. The method of claim 1, 2, 6, 10, or 11 wherein the phosphodiesterase inhibitor is sildenafil, desmethylsildenafil, vinopocetine, milrinone, amrinone, pimobendan, cilostamide, enoximone, peroximone, vesnarinone, rolipram, R020-1724, zaprinast, dipyridamole, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, prodrug, optically and pharmacologically active stereoisomer, or a pharmacologically active metabolite thereof.

20 16. A pharmaceutical composition comprising optically pure (-) sibutramine, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, or prodrug thereof, and a phosphodiesterase inhibitor.

25 17. The pharmaceutical composition of claim 16 wherein the phosphodiesterase inhibitor is sildenafil, desmethylsildenafil, vinopocetine, milrinone, amrinone, pimobendan, cilostamide, enoximone, peroximone, vesnarinone, rolipram, R020-1724, zaprinast, dipyridamole, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, prodrug, optically and pharmacologically active stereoisomer, or a pharmacologically active metabolite thereof.

30 18. The pharmaceutical composition of claim 16 wherein the optically pure (-) sibutramine is in an amount of from about 1 mg to about 60 mg.

19. The pharmaceutical composition of claim 18 wherein the optically pure (-) sibutramine is in an amount of from about 2 mg to about 50 mg.

5 20. The pharmaceutical composition of claim 19 wherein the optically pure (-) sibutramine is in an amount of from about 5 mg to about 30 mg.

21. The pharmaceutical composition of claim 16 wherein the phosphodiesterase inhibitor is in an amount of from about 0.5 mg to about 500 mg.

10

22. The pharmaceutical composition of claim 21 wherein the phosphodiesterase inhibitor is in an amount of from about 1 mg to about 350 mg.

23. The pharmaceutical composition of claim 22 wherein the
15 phosphodiesterase inhibitor is in an amount of from about 2 mg to about 250 mg.

24. The pharmaceutical composition of claim 16 wherein the pharmaceutical composition is adapted for oral, mucosal, rectal, parenteral, transdermal, or subcutaneous administration.

20

25. The pharmaceutical composition of claim 24 wherein the pharmaceutical composition is adapted for oral, mucosal, or transdermal administration.

A New Model of Chronic Visceral Hypersensitivity in Adult Rats Induced by Colon Irritation During Postnatal Development

ELIE D. AL-CHAEER, MOTOHIRO KAWASAKI, and PANKAJ J. PASRICHA

Division of Gastroenterology, Departments of Internal Medicine and Anatomy and Neurosciences, University of Texas Medical Branch, Galveston, Texas

Background & Aims: The irritable bowel syndrome (IBS) is a common disorder characterized by abdominal pain in the setting of altered perception of viscerosensory stimuli. This so-called visceral hyperalgesia occurs in the absence of detectable organic disease in the peripheral organs and may cause normal or physiologic contractions to be perceived as painful. Although the pathogenesis of IBS remains speculative and is probably multifactorial, a prevailing paradigm is that transient noxious events lead to long-lasting sensitization of the neural pain circuit, despite complete resolution of the initiating event. **Methods:** Neonatal male Sprague-Dawley rats received either mechanical or chemical colonic irritation between postnatal days 8 and 21 and were tested when they became adults. The abdominal withdrawal reflex and the responses of viscerosensitive neurons were recorded during colon distension. **Results:** Colon irritation in neonates, but not in adults, results in chronic visceral hypersensitivity, with characteristics of allodynia and hyperalgesia, associated with central neuronal sensitization in the absence of identifiable peripheral pathology. **Conclusions:** These results concur largely with observations in patients with IBS, providing a new animal model to study IBS and validating a neurogenic component of functional abdominal pain that encourages novel approaches to health care and research.

Pain, often viewed as a secondary and fleeting consequence of illness or injury, can become the consuming focus of a person's life when it is unremitting. This is particularly true when it occurs in the absence of any identifiable pathology, as in patients with irritable bowel syndrome (IBS), a condition that affects up to 15% of the U.S. population and has a significant socioeconomic impact.^{1,2} IBS is presently defined by a bundle of symptoms³ consisting mainly of recurrent abdominal pain associated with altered bowel movements. The original view of the disease as a primary disturbance in gut structure and/or function is being conceptually refined to include a complex and disordered interaction between the digestive and nervous systems.⁴

Although the relative roles of visceromotor, sensory, and affective factors⁵ in the pathophysiology of this syndrome are not well understood, a specific enhancement of visceral (as opposed to somatic) sensitivity to noxious as well as physiologic stimuli appears to be consistently present and is considered a clinical hallmark of the syndrome.¹ The etiology of this visceral hypersensitivity is probably multifactorial.⁶ In this study, we propose that transient noxious stimulation of the viscera in neonates, in which the nervous system is most vulnerable, can cause long-lasting sensitization of the neural pain circuit despite complete resolution of the initiating event. We present a relatively novel approach to understanding the pathogenesis of IBS. In particular, this study shows for the first time that abnormal events in the gastrointestinal tract during postnatal development can have a long-lasting impact on the neural processing of sensory information in adulthood. It also shows that functional abdominal pain can be modeled in animals and makes the case for a neurogenic basis of this pain using direct behavioral and electrophysiologic evidence. Preliminary results were previously reported in abstract form.⁷

Materials and Methods

Animals

Experiments were performed using male Sprague-Dawley rats obtained as preweanling neonates (younger than 8 days) from Harlan Sprague-Dawley Inc. (Indianapolis, IN). Rats were housed in plastic cages containing corn chip bedding (Sani-Chips; PJ Murphy Forest Products, Montville, NJ) and maintained on a 12/12-hour light-dark cycle (lights on at 7 AM). The irritation procedure and the experimental testing were conducted during the light component of the cycle. The neonates were housed 12 in a cage with 1 adult female until

Abbreviations used in this paper: AWR, abdominal withdrawal reflex; CI, colon irritation; CRD, colorectal distension; IBS, irritable bowel syndrome.
© 2000 by the American Gastroenterological Association
0016-5085/00/\$10.00
doi:10.1053/ga.2000.19576

they were 25 days old. The adult female had access to food and water ad libitum. After separation, the male rats were housed 4 in a cage with access to food and water ad libitum. At the weight of 250 g, only 2 rats from the same testing group (control, mechanically irritated, or chemically irritated) were together in any cage. All studies were performed in accordance with the proposals of the Committee for Research and Ethical Issues of the International Association for the Study of Pain⁸ and were approved by the Institutional Animal Care and Use Committee at the University of Texas Medical Branch in accordance with the guidelines provided by the National Institutes of Health.

Colon Irritation

Neonatal rats (8–21 days) were exposed to mechanical and chemical colon irritants for variable times and at different ages. The rats were then left to grow to adult age and tested for behavioral or neuronal responses to colorectal distension (CRD). Similar paradigms of colon irritation (CI) were used in perinatal (older than 21 days) or young adult (older than 40 days) rats to help determine the existence of a critical age at which CI can result in chronic visceral hypersensitivity.

Neonatal CI. Male Sprague-Dawley rats (8 days old) were divided into 3 groups undergoing different treatments.

Rats in group 1 received CRD on a daily basis between the ages of 8 and 21 days. The distension was applied using angioplasty balloons (Advanced Polymers Inc., Salem, NH, length, 20.0 mm; diameter, 3.0 mm) inserted rectally into the descending colon. The balloon was distended with 0.3 mL of water, exerting a pressure of 60 mm Hg (as measured with a sphygmomanometer), for 1 minute and then deflated and withdrawn. The distension was repeated 2 times (separated by 30 minutes) within an hour.

Rats in group 2 received intracolonic injections of mustard oil (0.2 mL, 5%) daily between the ages of 8 and 21 days. Mustard oil was injected into the colon via PE50 tubing inserted to 2 cm from the anus.

Rats in group 3 (control) were handled similarly to those in groups 1 and 2 except that no colonic insertion was made. Rats in this group were gently held and touched on the perineal area daily between the ages of 8 and 21 days. Group 3 served as a control for CI and is referred to as the control group.

The rats in each group were housed in cages with their mothers. No treatment, procedure, or further intervention was done by the investigator for 2 weeks starting postnatal day 21 (PN21).

Periadolescent and adult CI. Initially, periadolescent (irritation began at PN21) and young adult (irritation began at PN45) rats were treated as 2 separate groups. However, when the rats were later tested with CRD, they showed no significant differences in behavior. Male Sprague-Dawley rats (older than 21 days), obtained from the same source, were divided into 3 groups similar to those described for neonatal CI. The adult rats were sedated with an intraperitoneal injection of Brevital (0.5 mL, 1%) to facilitate placement of the




Figure 1. Timelines for CI and behavioral testing for neonatal (upper line) and adult (lower line) rats. CI began at age 8 days in neonates and 22 days in adults and continued for 2 weeks. It was followed by a resting period of 2 weeks. Rats were then tested on a weekly basis until age 3 months.

balloon or catheter into the descending colon and then allowed to wake up (Brevital, Jones Pharma, Inc., St. Louis, MO).

Rats in group 1 received daily CRD (80 mm Hg) using an inflatable balloon (constructed from a latex glove finger; length, 4 cm; inflated with air) attached to an intravenous line connected via a Y connector to a manual pump and a sphygmomanometer. The balloon was inserted into the colon while the animal was sedated, and CRD was induced while animals were fully awake. CRD was applied for 1 minute and repeated twice within an hour at an interval of 30 minutes.

Rats in group 2 received daily injections of mustard oil (0.5 mL, 5%) while sedated.

Rats in group 3 were sedated, allowed to wake up, and then gently handled by the investigator and touched in the perineal area. The schedule of procedures in adult groups was parallel in time to that in neonates (Figure 1).

Behavioral Testing

Behavioral responses to CRD were assessed in all groups starting 2 weeks after the cessation of the irritation protocol by measuring the abdominal withdrawal reflex (AWR) using a semiquantitative score or by measuring the threshold intensity of CRD that elicits an *escape contraction* in the abdominal wall musculature. The AWR is an involuntary motor reflex similar to the visceromotor reflex.⁹ However, the advantage of the AWR over the visceromotor reflex is that the latter requires additional surgery to implant recording electrodes and wires in the abdominal muscles, which may cause additional sensitization in an already sensitized system (CI rats). Dissection balloons (described below) were placed in the descending colons of mildly sedated adult rats (Brevital, 5 mL, 1% intraperitoneally) and secured by taping the attached tubing to the rat's tail. The rats were then housed in small Lucite cubicles (20 × 8 × 8 cm) on an elevated Plexiglas platform and allowed to wake up and adapt (1 hour). Measurement of the AWR consisted of visual observation of the animal response to graded CRD (20, 40, and 80 mm Hg) by blinded observers and assignment of an AWR score (AWR




Figure 2. Schematic drawings of rats on similar platforms illustrating the behavioral scale used for visual observations of the AWR in response to graded CRD. (1) The rat becomes immobile during the CRD and occasionally clenches the right jaw at the onset of the stimulus. (2) A mild contraction in the abdominal muscles is observed, but the rat does not lift its abdomen off the platform. (3) A strong contraction of the abdominal muscles is observed and the rat lifts its abdomen off the platform. (4) A severe contraction of the abdominal muscles is observed and the rat lifts its pelvic structures off the platform. (arrows point to the lifting of the abdomen and of the pelvic structures and scrotum).

scale: Figure 2). 0, no behavioral response to CRD; 1, brief head movement followed by immobility; 2, contraction of abdominal muscles; 3, lifting of abdomen; 4, body arching and lifting of pelvic structures.

Behavioral measurements were reproduced by 2 different blinded observers. Measuring the threshold intensity of CRD consisted of recording the stimulus intensity that evoked a visually identifiable contraction of the abdominal wall. CRD was applied in increments of 10 mm Hg starting at 10 mm Hg (the smallest distinguishable mark on the sphygmomanometer gauge).

For both measurements (AWR and thresholds), the rats were given CRD for 20 seconds every 4 minutes. To achieve an accurate measure, the distentions were repeated 5 times for each intensity. The data for each animal were averaged for analysis. The results obtained were compared across groups. A

change in the masticulate or the threshold of the evoked response indicated a change in visceral pain processing. These results were compared among groups (neonatal CRD or mustard oil; control; adult CI). This comparison allowed us to determine whether a postnatal time line exists during which CI can lead to long-lasting visceral hypersensitivity.

Electrophysiological Preparations

Surgical procedures. Adult male rats of either neonatal groups (CI or control) were initially anesthetized with pentobarbital (60 mg/kg, intraperitoneally). The trachea was intubated and a catheter was inserted into one of the jugular veins to allow a continuous infusion of the anesthetic (5 mg · kg⁻¹ · h⁻¹). Body temperature was monitored and kept around 37°C by a servo-controlled heated blanket. A laminectomy exposed the L6–S1 segments of the spinal cord. The rat was then moved to a shielded recording table. The head of the rat was fixed in a stereotaxic instrument, and the vertebral column was mounted on a spinal holder to minimize movements. The dura mater was cut, and the exposed spinal cord was covered with warm mineral oil.

Neuronal recordings. Recordings were made by a blinded investigator from individual neurons in the spinal gray matter of control rats or rats with neonatal CI using tungsten microelectrodes (125 µm, 12 MΩ). The recording electrode was initially placed near the midline, moved medially laterally at the level of 1 segment (on each side), then moved caudally spanning a depth of 1800 µm. This scheme minimized the damage to afferent input and allowed for observation of any lateralization of colonic input. Neuronal spikes were fed into a window discriminator and displayed on an oscilloscope screen. The output of both the window discriminator and the amplifier was fed into a data collection system (CED 1401+; Cambridge Electronic Design, Cambridge, England) and a personal computer to compile rate histograms or waveform files. Responses represent the total number of nerve impulses in excess of the number of background discharges that occur during the application of a stimulus. The measurements were compiled in a peristimulus time histogram. A period of 20 seconds of background activity was recorded, and a stimulus was applied. Cursors were set at the beginning and the end of the stimulus (generally a period of 10 or 20 seconds), and all the spikes that occurred between the cursors were summed. Cursors were also set at the beginning of the trace and after 10 seconds, and the spikes that occurred during this period were summed. This sum provides a measure of the background activity and is used to predict what the background activity would be during the stimulus. The 2 sums were divided by the respective duration, and the resulting averages (spikes/second) were subtracted to yield the value attributed to the response (total number of spikes/second in excess of the background activity during the stimulus).

Colon and somatic stimuli. Colon stimulation consisted of graded CRD produced by inflating a balloon inside the descending colon and rectum. The balloon was approximately 4 cm in length and was made of the finger of a latex

glove. It was attached to polyethylene tubing and inserted through the anus into the descending colon and rectum. The open end of the balloon was secured to the tubing with thread and wrapped with tape (1 cm wide). The balloon was inserted so that the thread was approximately 1 cm proximal to the anal sphincter. The balloon was held in place by taping the tubing to the tail. The tubing was attached via a T connector to a sphygmomanometer pump and gauge. Distention was produced by rapidly inflating the balloon to the desired pressure (20, 40, 60, or 80 mm Hg). Before they were used, the balloons were blown up and left overnight so the latex stretched and the balloons became compliant.

Somatic stimulation consisted of (1) innocuous brushing of an area of skin with repetitive strokes with a soft camel hair brush; (2) innocuous pressure on skin applied using a large arterial clip attached to a fold of skin (the clip exerts a pressure of 150 g/mm² and is not damaging or painful if applied to the skin of the experiment); (3) noxious pinch using a small arterial clip applied to a fold of skin (the clip exerts a pressure of 550 g/mm² and is painful when applied to the skin of the experiment); however, it does not produce overt damage to the skin; and (4) deep tissue stimulation using repetitive gentle pressures (2 seconds each for 10 seconds) applied against the body wall (body wall indentation) with the cotton end of a Q-tip.

Colon histology. At the end of the behavioral experiments, the distal 10 cm of the descending colon and rectum was removed, placed in 10% formalin, and sent for histologic processing. A cross section of the colon wall was fixed in formalin, dehydrated in graded alcohols and xylene, embedded in paraffin, and cut serially into 4–50-µm sections (8 µm apart) to be stained with H&E. Histology slides were stained using a CoolSNA camera (RS Photometrics, Tucson, Arizona) mounted on an Olympus microscope (Olympus America, Melville, NY). Image analysis was performed using MetaMorph Imaging System (Universal Imaging Corp., West Chester, PA). The severity of lesions in the colon was graded as follows: 1+, mild (infiltration of a low number of neutrophils in the lamina propria and little or no interstitial edema); 2+, moderate (infiltration of moderate numbers of neutrophils in the lamina propria and moderate interstitial edema); and 3+, severe (diffuse infiltration of moderate to large numbers of neutrophils in the lamina propria and severe interstitial edema). The severity of inflammation in colonic mucosa (none, mild, moderate, or severe) was graded after a blinded review by our gastrointestinal pathologist.

Statistical Analysis

The statistical analysis was done using SigmaStat (Jandel, SPSS Science, Chicago, IL).

Behavioral results. A Friedman test was used to assess if scores changed across pressures within each group. The differences in the median values of the AWR score among the 3 treatment groups (groups 1, 2, and 3) at each pressure of CRD were compared using the Kruskal–Wallis 1-way analysis of variance (ANOVA) on ranks. If the Kruskal–Wallis test

result was significant ($P < 0.05$), we performed pairwise comparisons using a Wilcoxon rank sum test with a Bonferroni correction at 0.05/3 to correct for multiple comparisons.

A 1-way ANOVA was performed to compare the differences in the median values of the thresholds to elicit a distinctive abdominal contraction measured in the 3 groups. This was followed by pairwise comparisons using a Bonferroni t test with a corrected P value of 0.05/3.

Statistical significant results refer to a P value of $<0.05/3$. **Electrophysiological results.** The differences in the median values of the neuronal responses to each intensity of CRD among the 3 treatment groups (groups 1, 2, and 3) were compared using the Kruskal–Wallis 1-way ANOVA on ranks. If the Kruskal–Wallis test result was significant ($P < 0.05$), we examined pairwise comparisons using the Dunn test with a Bonferroni correction at 0.05/3.

Statistical significant results refer to a P value of $<0.05/3$.

Results

CI in neonatal rats leads to a state of chronic visceral hypersensitivity in adults manifested by increased contractility of abdominal muscles and hyperexcitability of viscerosensitive neurons in the lumbar spinal cord. This hypersensitivity occurs in the absence of identifiable histopathology in the adult colon and does not alter the growth rate of the rats with CI. In fact, sections from the colons of 12 rats (4 with neonatal CRD, 4 with neonatal mustard oil treatment, and 4 controls) were examined. The tissues showed no significant structural damage or loss of crypts. Mucin depletion or increase in intraepithelial lymphocytes was not seen in any of the tissue examined. Slides from the 3 groups were rated as 1+.

Behavioral Study

Eight rats neonatally treated with repetitive colon distention (group 1) were tested with graded CRD as adults (ages 5, 6, and 7 weeks and 3 months). They showed a significant increase in AWR compared with control rats (Figure 3). The responses in group 1 were similar to those recorded in group 2 (treated neonatally with intracolonic injections of mustard oil). These changes (between CI groups and control) were significant for all intensities of CRD, indicating a shift in the dose–response between stimulus and response toward higher responses to lower-intensity stimuli.

The threshold to elicit a distinctive abdominal muscle contraction in response to CRD was measured in rats with neonatal CRD ($n = 6$; group 1), neonatal mustard oil-treated rats ($n = 6$; group 2), and control rats ($n = 6$; group 3). It decreased from 53.3 ± 2.8 mm Hg in the control group to 22.3 ± 3.0 mm Hg in the irritated groups.




Figure 3. Box plots illustrating the distribution and mean AWR scores of 3 groups of neonatally treated rats measured at age (A) 5 weeks, (B) 6 weeks, (C) 7 weeks, and (D) 8 months; control (□; n = 8; group 1), and rats that received intraplacental injections of mustard oil (■; n = 8; group 2). The AWR scores are measured in response to graded CRD (20, 40, 60, and 80 mmHg). The vertical box plot displays the interquartile range (25%–75%) and the median (thick line). The error bars define the 5th through 95th percentiles. Intraplacental pressure of <40 mm Hg would not be perceived as nociceptive in normal animals but becomes so in animals with neonatal CI; this phenomenon is typically referred to as visceral allodynia. *Significant difference between the responses of control and mechanically irritated rats (Bonferroni-corrected $P < 0.05/3$). **Significant difference in responses between control rats and rats neonatally treated with mustard oil (Bonferroni-corrected $P < 0.05/3$).

The behavioral responses of the rats that received CI after the age of PN21 (mechanical or chemical) were tested at the age of 7 weeks and 3 months. These responses did not differ significantly from those of the control groups.

Electrophysiological Study

Experiments were performed on 24 rats (8 with neonatal mechanical CI, 8 with neonatal chemical CI, and 8 controls). The responses of single viscerosensitive dorsal horn neurons located at L6–S1 spinal segments to CRD were recorded. Seventeen neurons were isolated and studied in rats with neonatal mechanical CI (group 1), 16 neurons in rats with neonatal chemical irritation (group 2), and 15 neurons in control rats (group 3, control). No significant differences were detected in either the baseline activity or the responses of neurons isolated in rats of the 2 groups with neonatal CI (groups 1 and 2). The baseline activity of the neurons ranged between 0 and 55 spikes/s for the rats in groups 1 and 2 and between 0 and 29 spikes/s for the control group. The average background firing rate (\pm SEM) of the neurons isolated from rats in group 1 or group 2 (25.0 ± 2.8 and 25.4 ± 3.7

spikes/s, respectively) was significantly higher than the average background activity of the neurons isolated in control-rats (control; 7.0 ± 1.4 spikes/s; Figures 4A and 5A).

Individual responses of 2 neurons to graded CRD are shown in Figure 4B. Comparison of the average responses of the neurons isolated in rats of the 3 groups shows that the average response to CRD in rats with neonatal CI was significantly higher than the average response to CRD in control rats for all intensities tested (Figure 5A).

The neurons isolated in rats of all 3 groups and tested with CRD were also examined for convergent input from somatic receptive fields. The skin receptive fields were located in the perineal region, on the flank and upper thigh ipsilateral to the recording site, and at the base of the tail. Deep somatic fields often were located below the cutaneous receptive field. The propensity to respond to deep somatic stimulation was higher in rats with neonatal CI (both groups) than in control rats. The individual firing rates of these neurons are illustrated in Figure 4C. An extensive overlap, particularly in response to skin stimulation (innocuous brushing, innocuous pressure,




Figure 4. Rate histograms compiled from the responses of 2 neurons isolated in rats with neonatal CI (group 1: upper row) and control rats (group 3: lower row) show (A) the baseline activity of each neuron, (B) the responses of each neuron to 20 or 60 mm Hg (CRD bar indicates duration of distention), and (C) the responses of each neuron to all modalities of somatic stimulation (BR, brush; PR, pinch; PI, pinch and DEEP, deep).

noxious pinch), was seen between the ranges of firing rates of neurons in rats of the 3 groups. On average, the differences in the mean values of the responses to brushing or pressing among the treatment groups were not great enough to exclude the possibility that the difference was caused by random sampling variability; there was not a statistically significant difference. However, there was a significant difference in the responses of neurons isolated in neonatally irritated rats (groups 1 and 2) and responses in control rats to pinching and deep tissue stimulation (Figure 5B), indicating the possibility of tenderness in the referred field to noxious cutaneous stimulation or deep probing of subcutaneous tissues.

Discussion

Pain is a central feature in the lives of patients with IBS; in the more severe cases, it can be prominent enough to give rise to the term "pain caret."¹⁰ The lack of overt visceral pathology, along with reported associations with childhood sexual, physical, and verbal abuse, has resulted in several psychologic hypotheses to explain this so-called functional abdominal pain.⁶ Alternatively, such pain may be the result of sensitization of the nervous system at a vulnerable state in its development. The

human body can be actively engaged in modulating the nociceptive input it is subjected to using multiple mechanisms to either increase or decrease the nociceptive input, the experience of pain, and the reflex responses to painful stimuli.^{11–14} These mechanisms involve transient functional changes in peripheral and central neuronal activity and long-lasting changes involving neuronal plasticity.^{15–18} Pain is normally evoked by stimuli that are sufficiently intense to activate high-threshold sensory fibers, which relay the signal to the spinal cord. However, tissue injury or inflammation may lead to profoundly increase pain sensitivity in which noxious stimuli generate a greater response (hyperalgesia) and stimuli that are normally innocuous elicit pain (allodynia). Hypersensitivity induced by repeated or persistent noxious stimuli is well documented. Clinically, it is a common observation that acute stimulation of the viscera or inflammation of some internal organs results in increased pain sensitivity.¹⁹ For instance, distension of the colon in normal subjects evokes a painful sensation whose intensity increases progressively with the application of repetitive stimuli of constant amplitude.^{20,21} However, the chronic visceral hypersensitivity observed in the absence of peripheral pathology, commonly described as




Figure 5. (A) Bar graphs illustrate the average background firing rate of nociceptive neurons isolated in control rats ($n = 15$) and in rats with neonatal CI (group 1, $n = 17$; group 2, $n = 16$). Line graphs illustrate the average responses to graded CRD (20, 40, 60, or 80 mm Hg) of the same nociceptive dorsal horn neurons. (B) Bar graphs illustrate the average responses to different modalities of somatic stimulation of nociceptive dorsal horn neurons isolated in the 3 rat groups (group 1, $n = 17$; group 2, $n = 16$; and control, $n = 15$). * Bonferroni-corrected $P < 0.05/3$.

functional abdominal pain, is poorly understood, in part because of the lack of a valid animal model.

The results of this study indicate that transient colonic irritation in the neonatal period can indeed result in chronic visceral hypersensitivity that persists through adulthood despite the absence of any identifiable histopathology. These observations concur with those usually made in patients with IBS, a syndrome characterized mainly by abdominal pain in the absence of peripheral injury. Furthermore, the visceral hypersensitivity seen in rats subjected to neonatal colonic irritation is associated with increased sensitivity of dorsal horn neurons recipient of colonic input. Finally, CRD in adult rats does not result in chronic visceral hypersensitivity. This finding may be attributed to a residual effect of the barbiturate given to the adult rats at the time of irritation on the memory of the event. However, it is more likely to be explained by a specific vulnerability of the nervous sys-

tem in the neonatal period manifested by long-term plasticity.

A New Animal Model for Chronic Visceral Pain

Among the criteria considered in developing models of pain in nonhuman animals, the most important are the noxious quality, the reproducibility and control of the stimulus, the quantification of the response, and the ability to use the model in nonanesthetized animals. Aligned with these requirements are a number of ethical considerations, including limitations on the intensity, duration, and timing of the stimuli and the ability of the animal to exhibit an escape response.²² Existing animal models of bowel pain have greatly enhanced our knowledge of the nociception and hyperalgesia associated with acute mechanical or inflammatory stimuli, induced by phasic or repetitive CRD,^{23,24} or induced by injection into the colon of inflammatory chemicals such as glycerol,²⁴ acetic acid,²⁵ mustard oil,²⁶ or zymosan²⁷ that largely mimic the symptoms of inflammatory bowel diseases but not IBS. The lack of a valid animal model of IBS has hampered research into the neurologic aspects of the disease.

In this model, we use balloon distention of the colon as a visceral stimulus. In awake rats, CRD produces an increase in arterial blood pressure, an increase in heart rate, and a visceromotor response that consists of a contraction of the petitoneal (skeletal) musculature in response to CRD.²⁸ These contractions, as monitored by a blinded observer, are graded with stimulus intensity and presumably correlate with a gradual intensification of viscerosensory perception that ranges from the least to the most painful and therefore provide an operant behavioral paradigm to test the responses to CRD. The rating of low and high levels of CRD in this study is consistent with psychophysical and pseudoaffective studies on the responses to CRD^{29,30} showing that the pain threshold for CRD is approximately 40 mm Hg. The assumption that high-intensity CRD is a noxious stimulus and low-intensity CRD is not follows behavioral studies in humans that have shown that CRD of intensity ≥ 40 mm Hg is painful.³⁰ In rats, Ness and Gebhart³¹ characterized the responses to CRD as noxious or non-noxious based on whether the CRD evoked a visceromotor response (mean threshold, 26.3 ± 1.4 mm Hg) or simply produced a relaxation of the anal sphincter (mean threshold, 13.2 ± 0.7 mm Hg). The threshold for nociception corresponded with the threshold to evoke a visceromotor response.³¹ In this study, similar considerations were followed to define innocuous or noxious CRD; the mean threshold to elicit a distinctive abdom-

inal contraction or a visually detected visceromotor response was 33.3 ± 2.8 mm Hg in control rats (group 3) and 22.3 ± 3.0 mm Hg in rats with neonatal CI (groups 1 or 2). This indicates that in control rats, stimuli of subthreshold intensities (i.e., 20 or 40 mm Hg) are nonnoxious, whereas stimuli of suprathreshold intensities (i.e., 60 or 80 mm Hg) are noxious. The higher threshold to nociception compared with that observed by Ness and Gebhart³¹ may be explained by the shorter balloon/tubing setup used in this study to allow more flexibility in the hind body of the rat and observation of a wider range of behaviors. Studies in humans indicate that pain is produced by distention of the gut at the lowest distending pressures when long continuous segments of gut are distended simultaneously.³² Differentiating noxious from nonnoxious intensities of CRD is particularly relevant to the definition of visceral allodynia and hyperalgesia (discussed below).

To study the behavioral effect of colon distention, we used a semiquantitative scale to measure the AWR in response to CRD. The AWR is an involuntary motor reflex similar to the visceromotor reflex.³³ It involves a supraspinal loop and is quantified by assigning a numerical score to the graded contractions of the abdominal muscles. The AWR is reproducible and graded with the intensity of the stimulus; it can be used to measure changes in the processing of visceral input in the same rat before and after a manipulation. The advantage of the AWR over other tests such as the visceromotor reflex is that the latter requires additional surgery to implant recording electrodes and wires in the abdominal muscles, which may cause additional sensitization in an already sensitized system. In these studies, we used a range of CRD intensities (20, 40, 60, and 80 mm Hg).

Innocuous intensities of CRD did not elicit a visually detected abdominal muscle contraction in control rats but evoked a nociceptive response in CI rats, indicating visceral allodynia. The aggravation of the responses to noxious CRD in CI rats compared with sham rats indicates visceral hyperalgesia.

Visceral Hypersensitivity: Allodynia or Hyperalgesia?

Most models of postinjury hypersensitivity revolve around the notion of central sensitization, which causes spinal cord neurons to enhance their excitability, acquire lower thresholds, or increase their responsiveness to peripheral stimuli. Central sensitization was proposed by Hardy et al.³⁴ to explain the development and spread of hyperalgesia after injury to the skin. Similar findings have been reported in recent years in studies on human subjects and experimental animals using intradermal

injections of capsaicin.^{35,36} Central sensitization also accompanies painful joint inflammation.³⁷ Furthermore, a growing body of scientific evidence points to a role of central sensitization in the hypersensitivity associated with acute or inflammatory visceral pain.³⁸⁻⁴¹ Therefore, it seems reasonable to propose that the persistent colon hypersensitivity observed in IBS is associated with central neuronal sensitization, manifested by an increase in neuronal excitability at spinal and possibly supraspinal levels. In this study, we have shown that spinal visceromotor neurons in rats with neonatal CI show signs of sensitization. These manifest as a heightened baseline firing rate of these neurons, a decreased threshold to activation by CRD, and exaggerated responses to CRD and somatic stimulation (intense and deep) compared with homologous neurons isolated from control rats. Whereas heightened somatic sensitivity has seldom been reported in association with acute visceral stimuli,⁴² (contrast with other results⁴³⁻⁴⁵), in this model of chronic visceral hypersensitivity there is a significant intensification of the neuronal responses to deep somatic stimulation within the perineal area. Referral of sensation, particularly pain, from one tissue to another is a common clinical phenomenon in musculoskeletal and visceral pain disorders and can be caused by convergence of peripheral afferents from skin, muscle, and viscera onto common central neurons. Furthermore, there seems to be a clinical impression that functional gastrointestinal disorders typically overlap with fibromyalgia in the same patient, suggesting a common cause.⁴² Further studies are needed to qualitatively define the nature of the heightened somatic responses in this model and the underlying mechanisms of somatic hypersensitivity.

The heightened visceral sensitivity of neonatally irritated rats has characteristics of both visceral allodynia, in which the response to an innocuous CRD is rendered equivalent to that of a noxious CRD, and visceral hyperalgesia, in which a noxious CRD can generate a greater response than normal. The term *visceral allodynia* is more appropriate in the context of a painless stimulus (innocuous stimulus or physiologic process) experienced as painful because of a preexisting condition (not necessarily at the site of stimulation), whereas the term *visceral hyperalgesia* is more appropriate in the context of unusually heightened sensitivity to normally painful stimuli. In psychophysical terms, hyperalgesia and allodynia are best understood as the consequences of a leftward shift that occurs in the curve relating stimulus intensity to pain sensation following peripheral injury.⁴⁶ This use of the nomenclature is in accordance with the recommendation of the International Association for the Study of Pain (IASP) on the description of the components of

hypersensitivity states.⁴⁴ Despite that, the scientific literature generated nowadays continues to be replete with inaccurate use of terminology particularly when it comes to the descriptors of visceral pain. Visceral hyperalgesia, for instance, has been commonly used in clinical settings to refer to visceral pain, often without distinction between pain caused by normal physiologic functions and exaggerated pain caused by normally painful procedures. However, the distinction between the phenomena is of great importance. Visceral pain is commonly present as a combination of several heterogeneous conditions resulting in multiple pain symptoms. These symptoms could be differentially mediated by sensitization of different types of visceral nociceptors,⁴¹⁻⁴⁴ by a "phenotypic switch" in a subpopulation of large afferent fibers,⁴⁹ or by central plastic changes manifested by increased excitability of viscerosensory neurons in the spinal cord and in supraspinal centers.^{11,19-21,30} Thus, it is important to distinguish between visceral allodynia and visceral hyperalgesia because they may have different underlying neuronal mechanisms and may require different approaches to treatment.

Long-term Effect of Neonatal Injury

Significant development of nociceptive neural circuits occurs during early postnatal life. Painful stimuli are normally absent or limited during this critical developmental period. Thus, when the pathways develop in the absence of noxious stimulation, pain represents a unique sensory stimulus. In the newborn organism, transient noxious stimuli have been shown to result in persistent alterations in afferent pathways.¹¹⁻¹⁴ In human neonates, sensitization can be produced by repeated mechanical stimulation or heel lances and in consequence of circumcision or surgery.^{11,13} The neonatal nervous system appears particularly vulnerable and susceptible to plastic changes. The newborn spinal cord is more excitable than that of the adult, and this has been associated with differences in the state of A-fiber-induced excitation (such that neonatal A-fibers can evoke excitatory synaptic processes normally restricted to C-fiber input in adults) as well as in the composition, concentration, and activity of N-methyl-D-aspartate receptors.¹⁴ In the adult, increases in excitability of the spinal cord nociceptive neurons induced by a sensitizing stimulus can be caused by the release of certain transmitters acting on the N-methyl-D-aspartate receptors,^{2,3,15-17} by the properties of the neuronal network activated by the stimuli, or both. Analysis of these changes, particularly the ones associated with persistent nociception, has generated a great deal of interest. It is currently believed that central plasticity plays a fundamental role in the generation and

maintenance of hyperalgesic pain states, and therefore its manipulation has become a target for potential therapies.

Conclusion

These observations demonstrate that the persistent visceral pain observed in the absence of identifiable pathology can be modeled in animals. This approach has potential for defining the pathophysiology of the visceral allodynia and hyperalgesia in functional abdominal disorders and hence should suggest ways the pain state may be ameliorated.

References

- Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. *Gastroenterology* 1997;112:2120-2137.
- Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. *Gastroenterology* 1987;92:1282-1284.
- Thompson WG, Drossman DA, Heaton KW, Knut SW. Irritable bowel syndrome: guidelines for the diagnosis. *Gastroenterol Int* 1989;2:92-95.
- Mayer EA, Minakata J, Mertz H, Lembo T, Bernstein CN. Visceral hyperalgesia and the irritable bowel syndrome. In: Gebhart GF, ed. *Visceral pain. Progress in pain research and management*. Volume 2. Seattle, WA: IASP, 1995:429-468.
- Lynn RB, Friedman L. Irritable bowel syndrome. *N Engl J Med* 1993;329:1940-1945.
- Pasricha PJ, Cowell ML, Tougas G. Approach to the patient with abdominal pain. In: Yamada T, ed. *Textbook of gastroenterology*. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999:795-815.
- Al-Chaer ED, Pasricha PJ. Transient colorectal irritation in the neonatal period produces long lasting visceral sensitization in rats: a potential model for IBS and other painful functional bowel disorders. *Gastroenterology* 1999;116:G4139.
- Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. *Pain* 1983;16:109-110.
- Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudoafferent reflexes in the rat. *Brain Res* 1988;450:153-169.
- Drossman DA. Chronic functional abdominal pain. *Am J Gastroenterol* 1996;91:2270-2281.
- Basbaum AI, Fields HL. Endogenous pain control systems: brain stem spinal pathways and endorphin circuitry. *Annu Rev Neurosci* 1984;7:309-338.
- Campbell JN, Raja SN, Cohen RH, Manning DC, Khan AA, Meyer RA. Peripheral neural mechanisms of nociception. In: Wall PD, Basbaum AI, eds. *Textbook of pain*. 2nd ed. Edinburgh: Churchill Livingstone, 1989:22-45.
- Fields HL, Basbaum AI. Endogenous pain control mechanisms. In: Wall PD, Melzack R, eds. *Textbook of pain*. 2nd ed. Edinburgh: Churchill Livingstone, 1989:206-219.
- Woolf CJ, Walters ET. Common patterns of plasticity contributing to nociceptive sensitization in mammals and Aplysia. *Trends Neurosci* 1991;14:74-78.
- Duggan WA, Morton CR. Tonic descending inhibition and spinal nociceptive transmission. In: Fields HL, Basbaum JM, eds. *Pain modulation*. Prog Brain Res 1986;71:193-211.
- Lumb BM. Brainstem control of visceral afferent pathways in the spinal cord. *Prog Brain Res* 1988;67:279-293.
- Willis WD Jr. Anatomy and physiology of descending control of
- nociceptive responses of dorsal horn neurons: comprehensive review. *Prog Brain Res* 1988;77:1-29.
- Cassey KL, ed. *Pain and central nervous system disease: the central pain syndromes*. New York, NY: Raven, 1991.
- Bontica JJ. The management of pain. 2nd ed. Philadelphia: Lea & Febiger, 1990.
- Ness TJ, Metzcalfe AM, Gebhart GF. A psychophysical study in humans using phasic colonic distension as a noxious visceral stimulus. *Pain* 1990;43:377-386.
- Munakata J, Naliboff B, Haral F, Kodner A, Lembo T, Chang L, Silverman DHS, Mayer EA. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. *Gastroenterology* 1997;112:55-63.
- Cassey KL, Dubner R. Animal models of chronic pain: scientific and ethical issues. *Pain* 1989;38:249-252.
- Gebhart GF, Sengupta JN. Evaluation of visceral pain. In: Gaglietta TS, ed. *Handbook of methods in gastrointestinal pharmacology*. New York: CRC, 1996:359-373.
- Bueno L, Delvaux M, Staumont G, Carman F, Fioramonti J, Bueno L, Freinios J. Intracolic injection of glycerol: a model for abdominal pain in irritable bowel syndrome. *Gastroenterology* 1996;110:351-361.
- Burton MB, Gebhart GF. Effects of intracolonic acetic acid on responses to colorectal distension in the rat. *Brain Res* 1995; 672:77-82.
- Jiang MC, Gebhart GF. Development of mustard oil-induced hyperalgesia in rats. *Pain* 1998;77:305-313.
- Coulinho SV, Meller ST, Gebhart GF. Intracolonic zymosan produces visceral hyperalgesia in the rat that is mediated by spinal NMDA and non-NMDA receptors. *Brain Res* 1996;736:7-15.
- Lewis TJ, Wolff HG, Goodell H. Pain sensations and reactions. New York: Williams & Wilkins, 1952. (Reprinted New York: Hafner, 1967.)
- LaMotte RH, Lundberg LE, Toibörk HE. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. *J Physiol* 1992;448:749-764.
- Toibörk HE, Lundberg LE, LaMotte RH. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. *J Physiol* 1992;448:765-780.
- Neugebauer V, Schallek HG. Evidence for a central component in the sensitization of spinal neurons with joint input during development of acute arthritis in cat's knee. *J Neurophysiol* 1990;64: 269-311.
- Coulinho SV, Urban MO, Gebhart GF. Role of glutamate receptors and nitric oxide in the rostral ventromedial medulla in visceral hyperalgesia. *Pain* 1998;78:59-69.
- Rozsa C, Laird JM, Cassey F. Spinal mechanisms underlying persistent pain and altered hyperalgesia in rats with an experimental allodynic state. *J Neurophysiol* 1998;79:1603-1612.
- Traub RJ, Silva E, Gebhart GF, Solodkin A. Noxious colorectal distension induces c-Fos protein in limbic brain structures in the rat. *Neurosci Lett* 1996;215:165-168.
- Laird JM, Roza C, Cassey F. Spinal dorsal horn neurons responding to noxious distension of the ureter in anesthetized rats. *J Neurophysiol* 1996;76:3239-3248.
- Ness TJ, Gebhart GF. Interactions between visceral and cutaneous nociceptive neurons and reflexes. *J Neurophysiol* 1991; 66:20-28.
- Ness TJ, Gebhart GF. Interactions between visceral and cutaneous nociception in the rat. II. Noxious visceral stimuli inhibit cutaneous nociceptive neurons and reflexes. *J Neurophysiol* 1991;66:29-39.
- Al-Chaer ED, Westlund KN, Willis WD. Potentiation of thalamic responses to colorectal distension by visceral inflammation. *Neuroreport* 1996;7:1635-1639.
- Al-Chaer ED, Westlund KN, Willis WD. The dorsal column: a possible role in visceral hyperalgesia. In: Jensen TS, Turner JA, Wessendorf-Hallin Z, eds. *Proceedings of the 8th world congress on pain*. Volume 8. Seattle, WA: IASP, 1997:839-853.
- Al-Chaer ED, Westlund KN, Willis WD. Effects of colon inflammation on the responses of postsynaptic dorsal column cells to visceral and cutaneous stimulation. *NeuroReport* 1997;8:3267-3273.
- Veale D, Kavanagh G, Fielding JF, Fitzgerald O. Primary allodynia and the irritable bowel syndrome: different expressions of a common pathogenic process. *Br J Rheum* 1991;30:220-222.
- Cervero F, Laird JM. Mechanisms of touch-evoked pain (allodynia): a new model. *Pain* 1996;68:13-23.
- Merskey H, Bogduk N, eds. *Classification of chronic pain*. 2nd ed. IASP Seattle, WA: IASP Press, 1994:209-214.
- Cervero F, Sann H. Mechanically evoked responses of afferent fibres innervating the guinea-pig's ureter: an in vitro study. *J Physiol* 1989;412:245-268.
- Jiang W, Koltzenburg M. On the function of spinal primary afferent fibres supplying colon and urinary bladder. *J Auton Nerv Syst* 1990;30(suppl):S89-S96.
- Häber H-J, Jiang W, Koltzenburg M. Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation at the urinary bladder in the cat. *J Physiol (Lond)* 1990;425:545-562.
- Gebhart GF. Peripheral contributions to visceral hyperalgesia (review). *Clin J Gastroenterol* 1999;13(suppl A):37A-41A.
- Neumann S, Doubil TP, Leslie T, Woolf CJ. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. *Nature* 1996;384:360-364.
- Cervero F, Laird JM, Pozo MA. Selective changes of receptive field properties of spinal nociceptive neurons induced by visceral noxious stimulation in the cat. *Pain* 1993;51:325-342.
- Andrews K, Fitzgerald M. The cutaneous withdrawal reflex in human neonates: sensitization, receptive fields, and effects of contralateral stimulation. *Pain* 1994;56:95-101.
- Fitzgerald M. Development of pain mechanisms. *Br Med Bull* 1991;47:667-675.
- Fitzgerald M, Millard C, Macintosh N. Cutaneous hypersensitivity following peripheral tissue damage in newborn infants and its reversal with topical anaesthesia. *Pain* 1983;39:31-36.
- Fitzgerald M, Jennings E. The postnatal development of spinal sensory processing. *Proc Natl Acad Sci U S A* 1999;96:7719-7722.
- Al-Chaer ED, Lewand NB, Westlund KN, Willis WD. Pelvic visceral input into the nucleus gracilis is largely mediated by the postsynaptic dorsal column pathway. *J Neurophysiol* 1996;76:2675-2690.
- Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. *Neurosci* 1983;306:686-688.
- Haley JE, Sullivan AF, Dickenson AH. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. *Brain Res* 1990;518:218-226.
- Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartate acid receptor activation: implications for the treatment of post-injury pain hypersensitivity states. *Pain* 1991;44:293-299.

Received September 8, 1999. Accepted June 21, 2000.

Address requests for reprints to: Elie D. Al-Chaer, Ph.D., Department of Internal Medicine and Anatomy and Neuroscience, University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555-0832. e-mail: eldchaer@utmb.edu; fax: (409) 747-2084. The authors thank Dr. Shu-Yuan Xian, Department of Pathology, University of Texas Medical Branch, for his expert evaluation of the colonic tissues.